• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Resolution peptide ends phase-I tests

Article

A new peptide-based radiopharmaceutical for detecting inflammatorydisease that is under development by Resolution Pharmaceuticalshas finished phase-I clinical testing, the company reported lastmonth. The technetium-labeled agent, RP128, performed as

A new peptide-based radiopharmaceutical for detecting inflammatorydisease that is under development by Resolution Pharmaceuticalshas finished phase-I clinical testing, the company reported lastmonth. The technetium-labeled agent, RP128, performed as expectedin tests conducted at the Free University of Brussels in Belgium,according to John Thornback, general manager of Mississauga, Ontario-basedResolution.

The company plans to begin phase-II clinical tests in the firstquarter to compare the performance of RP128 against other proceduresfor diagnosing inflammation. It also hopes to determine whichtypes of inflammatory disease the agent is most suited for, Thornbacksaid.

Resolution Pharmaceuticals is a joint venture between AllelixBiopharmaceuticals and Canadian radiopharmaceutical company NordionInternational. It began operations in 1993 and RP128 is its leadproduct, with other peptide-based imaging agents under development.The firm is planning a private stock placement shortly, Thornbacksaid.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.